RALYL (RALY RNA binding protein like) is an RNA-binding protein localized to the nucleus and nucleoplasm that functions as a regulator of mRNA stability and alternative splicing 1. In hepatocellular carcinoma, RALYL promotes stemness by sustaining TGF-β2 mRNA stability through decreased N6-methyladenosine (m6A) modification, subsequently activating TGF-β signaling and PI3K/AKT/STAT3 pathways 1. Conversely, in colorectal cancer, RALYL acts as a tumor suppressor by binding to HNRNPC to promote MNK2 alternative splicing toward the MNK2a isoform, which activates p38 MAPK signaling and inhibits proliferation 2. RALYL expression is significantly reduced in multiple malignancies including clear cell renal cell carcinoma, ovarian clear cell carcinoma, and colorectal cancer, correlating with poor prognosis, advanced tumor stage, and metastasis 342. Beyond cancer, RALYL functions as a hub gene associated with Alzheimer's disease reserve, with decreased expression correlating to AD progression and cognitive decline 5. Clinically, RALYL DNA methylation status demonstrates utility in cervical cancer screening as part of the WID-qCIN test for HPV-positive women, improving detection of cervical intraepithelial neoplasia 6. These findings suggest RALYL serves context-dependent roles as both a tumor promoter and suppressor depending on cancer type.